IPONZ

Marina Biotech this week announced that the Intellectual Property Office of New Zealand said it will grant the company a patent covering its unlocked nucleobase analog technology.

The deal with an undisclosed "major pharmaceutical company" is focused on the evaluation of Marina's proprietary amphoteric liposomal formulations for pulmonary delivery.

According to MDRNA, the application claims siRNAs and delivery systems with therapeutic potential.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.